The latest trend in the Big Pharma industry, given the dearth of new blockbusters coming through R&D, may be to go specialist, but it's still all relative. Pfizer Inc. 's co-promotion of Merck Serono SA 's interferon-beta drug Rebif for multiple sclerosis still involves a $550 million drug; Roche sells cancer products worth several hundred million in annual sales. These products may never be blockbusters, but they're still large enough to leave plenty of far smaller drugs off the bottom of pharma's priority list. Consolidation—both between Big Pharma and with biotechs—will likely continue to throw up stray compounds, or drugs which must be sold to satisfy increasingly stringent competition laws.
All of which endorses the strategy of firms like Amdipharm Mercury Ltd. , a wholly owned subsidiary of UK...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?